Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical Trial in a Dish: Using Patient-Derived Induced Pluripotent Stem Cells to Identify Risks of Drug-Induced Cardiotoxicity.

Arteriosclerosis, thrombosis, and vascular biology - 1 Mar 2021

Lam Chi Keung, Wu Joseph C

Abstract excerpt

Drug-induced cardiotoxicity is a significant clinical issue, with many drugs in the market being labeled with warnings on cardiovascular adverse effects. Treatments are often prematurely halted when cardiotoxicity is observed, which limits their therapeutic potential. Moreover, cardiotoxicity is a major reason for abandonment during drug development, reducing available treatment options for diseases and creating...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Arrhythmias, Cardiac
Share to Cardiotoxicity

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Evaluation, Preclinical

Share to Induced Pluripotent Stem Cells

Share to Myocardial Contraction

Share to Myocarditis

Share to Myocytes, Cardiac

Share to Pharmacogenomic Testing

Source

Open in PubMed Open full text

Identifiers

PMID: 33472401
DOI: 10.1161/ATVBAHA.120.314695
PMCID: PMC11006431

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical Trial in a Dish: Using Patient-Derived Induced Pluripotent Stem Cells to Identify Risks of Drug-Induced Cardiotoxicity.PMID 33472401Read ↗

Drug Development and the Use of Induced Pluripotent Stem Cell-Derived Cardiomyocytes for Disease Modeling and Drug Toxicity ScreeningSemantic proximity Read ↗

Personalized medicine in cardio-oncology: the role of induced pluripotent stem cellSemantic proximity Read ↗

Drug screening using a library of human induced pluripotent stem cell-derived cardiomyocytes reveals disease-specific patterns of cardiotoxicity.Semantic proximity Read ↗

Human induced pluripotent stem cell (iPSC)-derived cardiomyocytes as an in vitro model in toxicology: strengths and weaknesses for hazard identification and risk characterizationSemantic proximity Read ↗

Moving beyond the comprehensive in vitro proarrhythmia assay: Use of human-induced pluripotent stem cell-derived cardiomyocytes to assess contractile effects associated with drug-induced structural cardiotoxicity.Semantic proximity Read ↗

Validating the pharmacogenomics of chemotherapy-induced cardiotoxicity: What is missing?Semantic proximity Read ↗

Understanding the Mechanisms of Chemotherapy-Related Cardiotoxicity Employing hiPSC-Derived Cardiomyocyte Models for Drug Screening and the Identification of Genetic and Epigenetic VariantsSemantic proximity Read ↗

Modeling Doxorubicin-Induced Cardiotoxicity in Human Pluripotent Stem Cell Derived-CardiomyocytesSemantic proximity Read ↗

Concise Review: Drug Discovery in the Age of the Induced Pluripotent Stem CellSemantic proximity Read ↗

Pediatric Anthracycline‐Induced Cardiotoxicity: Mechanisms, Pharmacogenomics, and Pluripotent Stem‐Cell ModelingSemantic proximity Read ↗

Human In Vitro Models for Assessing the Genomic Basis of Chemotherapy-Induced Cardiovascular Toxicity.Semantic proximity Read ↗

Cardiac safety pharmacology: from human ether-a-gogo related gene channel block towards induced pluripotent stem cell based disease models.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.